|1.||Khavinson, V Kh: 3 articles (02/2013 - 10/2007)|
|2.||Linkova, N S: 1 article (02/2013)|
|3.||Tarnovskaya, S I: 1 article (02/2013)|
|4.||Kvetnoy, I M: 1 article (02/2013)|
|5.||Kvetnaia, T V: 1 article (02/2013)|
|6.||Tolibova, G H: 1 article (02/2013)|
|7.||Polyakova, V O: 1 article (02/2013)|
|8.||Durnova, A O: 1 article (02/2013)|
|9.||Korkushko, O V: 1 article (08/2011)|
|10.||Antonyk-Sheglova, I A: 1 article (08/2011)|
10/01/2007 - "The results indicate homeostatic and endothelioprotective effects of pancragen during the early period of diabetes mellitus."
02/01/2013 - "Thus, transcription factors that regulate differentiation of pancreatic cells are a pharmacological target for pancragen, which allows considering it as an effective tool in the treatment of diabetes mellitus and pancreatitis."
10/01/2007 - "The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus. "
08/01/2011 - "Administration of the tetrapeptide pancragen is a promising approach to the correction of insulin resistance in elderly individuals."
08/01/2011 - "In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index. "
|4.||Experimental Diabetes Mellitus
|1.||Transcription Factors (Transcription Factor)
|5.||Blood Glucose (Blood Sugar)